A biomimetic collagen derived peptide exhibits anti- Angiogenic activity in triple negative breast cancer

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Rosca, Elena V ^a   Penet, Marie France ^b   Mori, Noriko ^b   Koskimaki, Jacob E ^a   Lee, Esak ^a   Pandey, Niranjan B ^a   Bhujwalla, Zaver M ^b,c   Popel, Aleksander S ^a,c  

^a Johns Hopkins University   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CASPASE 3; LEUCYLARGINYLARGINYLPHENYLALANYLSERYLTHREONYLALANYLPROLYLPHENYLALANYLALANYLPHENYLALANYLISOLEUCYLPROLYLGLUTAMYLALANYLLYSYLVALYLISOLEUCYLASPARAGINYLPHENYLALANINE AMIDE; LEUCYLARGINYLARGINYLPHENYLALANYLSERYLTHREONYLMETHIONYLPROLYLPHENYLALANYLMETHIONYLPHENYLALANYLISOLEUCYLASPARAGINYLISOLEUCYLASPARAGINYLASPARAGINYLVALYLISOLEUCYLASPARAGINYLPHENYLALANINE AMIDE; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG; COLLAGEN TYPE 4; PEPTIDOMIMETIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CANCER INHIBITION; CAPILLARY DENSITY; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MDA MB 231 CELL LINE; MOUSE; NONHUMAN; TREATMENT DURATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL; TUMOR VOLUME; TUMOR XENOGRAFT; AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; MOLECULAR GENETICS; PATHOLOGY; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE; VASCULARIZATION;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; COLLAGEN TYPE IV; HUMANS; MICE; MOLECULAR SEQUENCE DATA; PEPTIDOMIMETICS; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84911378160     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111901     Document Type: Article

References (33)

1. Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186.
2. Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29: 15-18.
3. Backer MV, Backer JM (2012) Imaging key biomarkers of tumor angiogenesis. Theranostics 2: 502-515.
4. Miklos GL (2012) Bevacizumab in neoadjuvant treatment for breast cancer. N Engl J Med 366: 1638; author reply 1639-1640.
5. Braghiroli MI, Sabbaga J, Hoff PM (2012) Bevacizumab: overview of the literature. Expert Rev Anticancer Ther 12: 567-580.
6. Preusser M, Fulop G, Berghoff AS, Heinzl H, Steger GG, et al. (2012) Influence of the American ODAC Statement on Austrian Bevacizumab Prescribing Practice for Metastatic Breast Cancer. Oncologist 17: e13-17.
7. Mena AC, Pulido EG, Guillen-Ponce C (2010) Understanding the molecularbased mechanism of action of the tyrosine kinase inhibitor: sunitinib. Anticancer Drugs 21 Suppl 1: S3-11.
8. Rose S (2011) FDA pulls approval for avastin in breast cancer. Cancer Discov 1: OF1-2.
9. Shojaei F (2012) Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett 320: 130-137.
10. Rosca EV, Koskimaki JE, Rivera CG, Pandey NB, Tamiz AP, et al. (2011) Antiangiogenic peptides for cancer therapeutics. Curr Pharm Biotechnol 12: 1101-1116.
11. Manegold C, Vansteenkiste J, Cardenal F, Schuette W, Woll PJ, et al. (2012) Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-smallcell lung cancer. Invest New Drugs.
12. Nabors LB, Fiveash JB, Markert JM, Kekan MS, Gillespie GY, et al. (2010) A phase 1 trial of ABT-510 concurrent with standard chemoradiation for patients with newly diagnosed glioblastoma. Arch Neurol 67: 313-319.
13. Rosca EV, Koskimaki JE, Pandey NB, Tamiz AP, Popel AS (2012) Structureactivity relationship study of collagen-derived anti-angiogenic biomimetic peptides. Chem Biol Drug Des 80: 27-37.
14. Koskimaki JE, Karagiannis ED, Tang BC, Hammers H, Watkins DN, et al. Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model. BMC Cancer 10: 29.
15. Rivera CG, Rosca EV, Pandey NB, Koskimaki JE, Bader JS, et al. (2011) Novel peptide-specific quantitative structure-activity relationship (QSAR) analysis applied to collagen IV peptides with antiangiogenic activity. J Med Chem 54: 6492-6500.
16. Karagiannis ED, Popel AS (2008) A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells. Proc Natl Acad Sci U S A 105: 13775-13780.
17. Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10: 9-22.
18. Ivaska J, Heino J (2011) Cooperation between integrins and growth factor receptors in signaling and endocytosis. Annu Rev Cell Dev Biol 27: 291-320.
19. Pathak AP, Hochfeld WE, Goodman SL, Pepper MS (2008) Circulating and imaging markers for angiogenesis. Angiogenesis 11: 321-335.
20. Glunde K, Jacobs MA, Pathak AP, Artemov D, Bhujwalla ZM (2009) Molecular and functional imaging of breast cancer. NMR Biomed 22: 92-103.
21. Pathak AP, Penet MF, Bhujwalla ZM (2010) MR molecular imaging of tumor vasculature and vascular targets. Adv Genet 69: 1-30.
22. Raatschen HJ, Simon GH, Fu Y, Sennino B, Shames DM, et al. (2008) Vascular permeability during antiangiogenesis treatment: MR imaging assay results as biomarker for subsequent tumor growth in rats. Radiology 247: 391-399.
23. Ogan MD, Schmiedl U, Moseley ME, Grodd W, Paajanen H, et al. (1987) Albumin labeled with Gd-DTPA. An intravascular contrast-enhancing agent for magnetic resonance blood pool imaging: preparation and characterization. Invest Radiol 22: 665-671.
24. Koskimaki JE, Karagiannis ED, Rosca EV, Vesuna F, Winnard PT Jr, et al. (2009) Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts. Neoplasia 11: 1285-1291.
25. Bhujwalla ZM, Artemov D, Natarajan K, Solaiyappan M, Kollars P, et al. (2003) Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470. Clin Cancer Res 9: 355-362.
26. Karagiannis ED, Popel AS (2007) Identification of novel short peptides derived from the alpha 4, alpha 5, and alpha 6 fibrils of type IV collagen with antiangiogenic properties. Biochem Biophys Res Commun 354: 434-439.
27. Goel S, Fukumura D, Jain RK (2012) Normalization of the tumor vasculature through oncogenic inhibition: an emerging paradigm in tumor biology. Proc Natl Acad Sci U S A 109: E1214.
28. Banerji S, Ni J, Wang SX, Clasper S, Su J, et al. (1999) LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 144: 789-801.
29. Imoukhuede PI, Popel AS (2014) Quantitative fluorescent profiling of VEGFRs reveals tumor cell and endothelial cell heterogeneity in breast cancer xenografts. Cancer Med. 3(2): 225-44.
30. Lakshmikanthan S, Sobczak M, Chun C, Henschel A, Dargatz J, et al. (2011) Rap1 promotes VEGFR2 activation and angiogenesis by a mechanism involving integrin alphavbeta(3). Blood 118: 2015-2026.
31. Montenegro CF, Salla-Pontes CL, Ribeiro JU, Machado AZ, Ramos RF, et al. (2012) Blocking alphavbeta3 integrin by a recombinant RGD disintegrin impairs VEGF signaling in endothelial cells. Biochimie 94: 1812-1820.
32. West XZ, Meller N, Malinin NL, Deshmukh L, Meller J, et al. (2012) Integrin beta3 crosstalk with VEGFR accommodating tyrosine phosphorylation as a regulatory switch. PLoS One 7: e31071.
33. Somanath P.R. Malinin N.L. Byzova T.V. 2009 Cooperation between integrin alphavbeta3 and VEGFR2 in angiogenesis. Angiogenesis 12 177-185